Taysha Gene Therapies
Motor Gains Observed in First Four Adults, Children to Get Taysha's Rett Syndrome Gene Therapy
Premium
The firm presented results from two adults and two children to receive a low-dose of its TSHA-102 gene therapy as it moves into high-dose cohorts.
In Brief This Week: Immix Biopharma, Carsgen Therapeutics, Color Health, Immunovia
News items for the week of April 29, 2024.
Taysha Gene Therapies Transfers IP for Five Programs to Extend Cash Runway Into 2026
The firm has transferred rights to collaborators and originating institutions for the programs as it focuses on its lead candidate for Rett syndrome.
Taysha Gene Therapies Gets $40M in Term Loans to Support Rett Syndrome Gene Therapy Development
The term loans, provided by Trinity Capital, are expected to fund the firm's operating expenses and capital requirements into 2026.
In Brief This Week: Sernova, Akeso, RoslinCT, GeNeuro, Effector Therapeutics, ARUP Laboratories
News items for the week of Nov. 27, 2023.